<DOC>
	<DOCNO>NCT00584584</DOCNO>
	<brief_summary>This study investigate whether single dose QAX576 ( interleukin-13 monoclonal antibody ) give protection model hayfever</brief_summary>
	<brief_title>An Exploratory Study Effects Single Dose QAX576 ( Interleukin-13 Monoclonal Antibody ) Simulated Hayfever</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>History allergic rhinitis . Respiratory disease mild intermittent asthma . Received immunotherapy past 3 year . History clinically significant drug allergy . History clinical schistosomiasis travel within 6 month prior follow study area endemic schistosomiasis . History exposure human therapeutic antibody , immunoglobulin plasma product . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Allergic rhinitis , adult , monoclonal antibody , interleukin-13 .</keyword>
</DOC>